The S-4/A is a procedural step toward the reverse merger. The key catalysts are the Fulcrum stockholder vote and Nasdaq listing approval. Monitor for the proxy mailing and the special meeting date. The ~$270M special dividend provides a near-term cash return to Fulcrum holders, but post-merger equity value depends entirely on Slate's clinical execution for SLTE-1009.
Price Chart
Executive Summary
Fulcrum Therapeutics (FULC) filed Amendment No. 1 to its S-4 registration statement on October 8, 2026, in connection with its proposed reverse merger with privately-held Slate Medicines. Under the merger agreement, Slate will effectively acquire Fulcrum in a reverse recapitalization: pre-merger Slate stockholders (excluding concurrent investors) will own ~55.9% of the combined company, new investors in a concurrent $245M Slate financing will own ~39.1%, and pre-merger Fulcrum stockholders will own ~5.0%. Fulcrum stockholders will receive a ~$270M pre-closing special cash dividend. The combined company will be renamed Slate Medicines, Inc. and trade under the symbol SLTE, with Slate's management and board in control. The merger is expected to close in Q4 2026, subject to Fulcrum stockholder approval and other conditions.
Key Facts
- Fulcrum and Slate entered into a merger agreement on August 16, 2026; Slate will be the accounting acquirer in a reverse recapitalization.
- Pre-merger Slate stockholders (excluding concurrent investors) expected to own ~55.9%, new investors ~39.1%, pre-merger Fulcrum stockholders ~5.0% of the combined company on a fully diluted basis.
- Slate Concurrent Investment of ~$245 million from existing and new investors; ~$160M from existing Slate investors.
- Fulcrum stockholders to receive a pre-closing special cash dividend of approximately $270 million.
- Fulcrum's valuation assumed at $31.3 million (subject to downward adjustment if net cash < $20.3M); Slate valued at $350 million.
- Combined company will trade on Nasdaq under symbol SLTE; Fulcrum renamed Slate Medicines, Inc.
- Slate's management team and board will control the combined company; all five board members designated by Slate.
- Merger expected to close Q4 2026.
- Fulcrum discontinued its pociredir program and reduced workforce by ~85% in June 2026.
- Slate's SLTE-1009 is in Phase 1 clinical trial in Australia (started August 2026).
Financial Impact
Fulcrum stockholders will receive a ~$270M pre-closing cash dividend. Their ownership in the combined company will be diluted to ~5.0% of the combined company. The combined company will have ~$245M from the Slate Concurrent Investment.
Risk Factors
- Failure to obtain Fulcrum stockholder approval for the merger proposals.
- Nasdaq listing condition not met or waived.
- Slate's SLTE-1009 is in early clinical development (Phase 1) and may fail.
- Combined company will need substantial additional capital.
- Pre-merger Fulcrum stockholders will own only ~5.0% of the combined company.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-418056 |
| Document: d127837dex231.htm | 0001193125-26-418056 |
| Document: d127837dex232.htm | 0001193125-26-418056 |
| Document: 0001193125-26-418056-index-headers.html | 0001193125-26-418056 |
| Document: 0001193125-26-418056.txt | 0001193125-26-418056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | S-4/A | $3.70 $3.68 | ▲ +0.54% | ▼ −0.64% | $3.65 (+1.22%) |
Oct 8, 2026 18d ago | S-4/A | $3.77 $3.75 | ▼ −0.53% | ▼ −0.47% | $3.65 (−3.05%) |
Sep 1, 2026 7w ago | S-4 | $3.85 $3.84 | ▲ +0.26% | ▲ +1.31% | $3.65 (+5.06%) |
Aug 17, 2026 10w ago | 425 | $3.84 $3.87 | ▼ −0.78% | ▼ −1.46% | $3.65 (+4.82%) |
Aug 17, 2026 10w ago | 425 | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.65 (−4.82%) |
Aug 17, 2026 10w ago | 8-K | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.65 (−4.82%) |
Aug 17, 2026 10w ago | Press Release | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.65 (−4.82%) |
Aug 10, 2026 11w ago | 8-K | $3.75 $3.69 | ▼ −1.60% | ▼ −1.28% | $3.65 (−2.53%) |
Jul 15, 2026 14w ago | 3 | $3.50 $3.65 | ▲ +4.29% | ▲ +5.28% | $3.65 (+4.43%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.55 $3.45 | ▼ −2.82% | ▼ −3.36% | $3.65 (+2.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers